RT Journal Article
SR Electronic
T1 Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4055
OP 4060
DO 10.21873/anticanres.16594
VO 43
IS 9
A1 AKINORI MINATO
A1 RIEKO KIMURO
A1 DAICHI OHNO
A1 KENTAROU TANIGAWA
A1 KEISUKE KURETAKE
A1 TAKUO MATSUKAWA
A1 TOMOHISA TAKABA
A1 KAZUMASA JOJIMA
A1 MIRII HARADA
A1 KATSUYOSHI HIGASHIJIMA
A1 YUJIRO NAGATA
A1 IKKO TOMISAKI
A1 KENICHI HARADA
A1 NAOHIRO FUJIMOTO
A1 HIROSHI MIYAMOTO
YR 2023
UL http://ar.iiarjournals.org/content/43/9/4055.abstract
AB Background/Aim: This study retrospectively investigated the impact of enfortumab vedotin (EV) monotherapy on the oncological outcome, safety profile, and health-related quality of life (HRQoL) in patients with metastatic urothelial carcinoma. Patients and Methods: We assessed 26 consecutive patients who had received EV monotherapy after failure of platinum-based chemotherapy and immune checkpoint blockade therapy at our single institution from December 2021 to January 2023. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), incidence of adverse events (AEs), and EORTC QLQ-C30 as an HRQoL instrument were evaluated. Results: The ORR and DCR were 57.7% and 80.8%, respectively. EV was effective regardless of the patient and tumor characteristics, including the efficacy of previous systemic therapy, performance status, number of Bellmunt risk factors, and presence of variant histology. With a median follow-up time of 7.5 months, the median durations of PFS and OS were 5.4 months and 10.3 months, respectively. Grade ≥3 AEs included neutropenia (15.4%), fatigue (7.7%), appetite loss (7.7%), rash (3.8%), febrile neutropenia (3.8%), hyperglycemia (3.8%), and interstitial pneumonia (3.8%). AEs resulting in withdrawal of EV, interruption of EV, and dose reduction occurred in two (7.7%), nine (34.6%), and 13 patients (50.0%), respectively. The EORTC QLQ-C30 scores from baseline to post-EV introduction remained stable. Conclusion: EV monotherapy demonstrated promising anti-tumor activity and tolerability in patients with metastatic urothelial carcinoma.